Work

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

Year: 2015

Type: article

Abstract: Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.01165-15

Authors: Romney M. Humphries, Shangxin Yang, Peera Hemarajata, Kevin W. Ward, Janet A. Hindler, Shelley A. Miller, Aric Gregson

Institution: University of California, Los Angeles

Language: English

Topic: Antibiotic Resistance in Bacteria

Subfield: Molecular Medicine

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W1547203214

FWCI: 11.08

Cites: 13

Cited by: 256

Related to: 10